Lead Product(s) : Daraxonrasib,Ivonescimab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Summit Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Revolution and Summit Collaborates to Evaluate RAS(ON) Inhibitors with Ivonescimab
Details : The collaboration aims to evaluate clinical-stage RAS(ON) inhibitors, including RMC-6236 (daraxonrasib), RMC-9805 (zoldonrasib) and RMC-6291 (elironrasib), in combination with ivonescimab.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 30, 2025
Lead Product(s) : Daraxonrasib,Ivonescimab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Summit Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Royalty Pharma
Deal Size : $1,250.0 million
Deal Type : Financing
Revolution Medicines Enters into $2 Billion Flexible Funding Agreement with Royalty Pharma
Details : The financing aims to advance the development and global commercialization of Revolution's leading RAS(ON) inhibitor portfolio, RMC-6236 (daraxonrasib), is being evaluated for RAS-mutated NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 24, 2025
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Royalty Pharma
Deal Size : $1,250.0 million
Deal Type : Financing
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolution Medicines Doses First Patient in Phase 3 Trial of Daraxonrasib
Details : RMC-6236 (daraxonrasib) is an oral, direct RAS(ON) multi-selective inhibitor with the potential to help address a wide range of cancers driven by oncogenic RAS mutations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2025
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301)
Details : Daraxonrasib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $862.5 million
Deal Type : Public Offering
Revolution Medicines Closes $750M Offering with Full Exercise of Additional Shares
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 05, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $862.5 million
Deal Type : Public Offering
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $750.0 million
Deal Type : Public Offering
Revolution Medicines Prices Upsized $750M Offering of Stock & Pre-Funded Warrants
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $750.0 million
Deal Type : Public Offering
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : J.P. Morgan
Deal Size : $600.0 million
Deal Type : Public Offering
Revolution Medicines Announces Commencement of Public Offering of Common Stock
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 02, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : J.P. Morgan
Deal Size : $600.0 million
Deal Type : Public Offering
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolution Medicines Doses First Patient in Phase 3 Metastatic Pancreatic Trial
Details : RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for previously treated pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RMC-6236 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolution Medicines to Update RMC-6236 Pancreatic Cancer Program on July 15, 2024
Details : RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for the treatment of pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable